Tom Dønnem

Tom Dønnem serves as Professor at the Department of Clinical Medicine, UiT The Arctic University of Norway, concurrently holding leadership as Head of the Translational Cancer Research Group (TCRG) and clinical duties as Consultant Oncologist at the University Hospital of North Norway in Tromsø. His dual academic-clinical role bridges fundamental research with patient care in Northern Norway's unique healthcare context.

Dr. Dønnem's research centers on translational cancer mechanisms with emphasis on tumor immunology and angiogenesis in lung cancer, extending to precision medicine applications across malignancies and palliative care systems. His work investigates immune cell dynamics (particularly TILs and tertiary lymphoid structures), molecular biomarkers (microRNAs, genomic signatures), and AI-driven diagnostic tools. Recent projects integrate machine learning with histopathology to predict immunotherapy responses and refine cancer staging, reflecting his commitment to clinically actionable discoveries.

Analysis of his 15 most recent publications (2019-2024) reveals three dominant trajectories: (1) AI-powered quantification of tumor immune microenvironments for NSCLC prognostication, (2) molecular biomarker discovery in liquid biopsies for early lung cancer detection, and (3) clinical validation of immune-based staging systems. His collaborative work spans oncology, cardiology, and rural healthcare, demonstrating methodological versatility while maintaining lung cancer as the primary disease focus.

Scientific awards are not referenced in the provided materials.

While specific advising details are unreported, his leadership of the TCRG and extensive co-authorship on student-involved projects (evident in publication patterns) indicate active mentorship. Grant funding is implied through multi-institutional trials like TNM-I but not itemized.

Dr. Dønnem directs the Translational Cancer Research Group operating from MH øst L8.131 in Tromsø, with primary projects including the TNM-Immune Cell Score Trial, Prognostic Biomarkers initiative, Tumors Angiogenesis program, and Genomic Profiling consortium. These teams leverage both traditional pathological analysis and cutting-edge computational approaches to address cancer heterogeneity and treatment resistance.